Skip Navigation LinksHome > March 2014 - Volume 21 - Issue 2 > Beyond hypomethylating agents failure in patients with myelo...
Current Opinion in Hematology:
doi: 10.1097/MOH.0000000000000016
MYELOID DISEASE: Edited by Martin S. Tallman

Beyond hypomethylating agents failure in patients with myelodysplastic syndromes

Zeidan, Amer M.a; Kharfan-Dabaja, Mohamed A.b; Komrokji, Rami S.c

Collapse Box

Abstract

Purpose of review

Although hypomethylating agents (HMAs) significantly improve outcomes in myelodysplastic syndromes (MDS), only half the patients achieve objective responses, and most responders lose response within 1–2 years. Azacitidine prolongs survival by a median of only 9.5 months. Failure of HMA therapy is associated with a very dismal prognosis. Therefore, novel therapeutic approaches are clearly needed.

Recent findings

The sequential use of the alternative HMA after failure of first line HMA is associated with modest efficacy. The improved understanding of the biologic underpinnings of the disease have opened the door to study investigational agents that target disrupted molecular pathways critical to the pathogenesis of MDS. Combination treatment strategies using an azacitidine backbone are demonstrating promising early results. Expanding the applicability of allogeneic stem cell transplantation (alloSCT), the only curative modality, by reducing toxicity and relapse rates is another area of active research.

Summary

Sequential switching to the alternative HMA, clinical trials of novel targeted therapies, azacitidine-based combination therapeutic strategies, and improvements in the alloSCT platform are the main directions in improving outcomes of MDS post HMA failure.

© 2014 Wolters Kluwer Health | Lippincott Williams & Wilkins

Login

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.